Table 1.
Patient characteristics.
| N (%) or median(range) | |
|---|---|
| Total | 128 (100) |
| Age | 62 (21–82) years |
| Sex | |
| Male | 89 (69.5) |
| Female | 39 (30.5) |
| ECOG PS | |
| 0 | 27 (21.1) |
| 1 | 98 (76.6) |
| 2 | 1 (0.8) |
| Unknown | 2 (1.6) |
| Diagnosis | |
| NSCLC | 50 (39.1) |
| Melanoma | 31 (24.2) |
| SCLC | 14 (10.9) |
| UCC | 13 (10.2) |
| RCC | 6 (4.7) |
| HNSCC | 5 (3.9) |
| Salivary gland cancer | 4 (5.8) |
| Others | 5 (3.9) |
| History of radiotherapy* | |
| Never irradiated | 50 (39.1) |
| Received radiotherapy | 78 (60.9) |
| Within 4 weeks to ICI treatment | 14 (17.9) |
| Earlier than 4 weeks | 43 (55.1) |
| After end of ICI treatment | 21 (26.9) |
| Type of ICI treated† | |
| Monotherapy | |
| Nivolumab | 41 (32.0) |
| Pembrolizumab | 32 (25.0) |
| Durvalumab | 15 (11.7) |
| Ipilimumab | 5 (3.9) |
| Atezolizumab | 4 (3.1) |
| Combination therapy | |
| Pembrolizumab/other | 13 (10.2) |
| Atezolizumab/other | 13 (10.2) |
| Nivolumab and ipilimumab | 2 (1.6) |
| Others | 3 (2.3) |
ECOG PS eastern cooperative oncology group performance status, NSCLC non-small cell lung cancer, SCLC small cell lung cancer, UCC urothelial carcinoma, RCC renal cell carcinoma, HNSCC head and neck squamous cell carcinoma, ICI immune checkpoint inhibitor.
*Encompasses all types of radiotherapy, including stereotactic radiosurgery.
†Denotes patients who received ICI as part of a clinical trial.